Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:00 ET | Trevena Inc.
CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting
September 21, 2020 07:00 ET | Trevena Inc.
-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting Posters on OLINVYK benefit-risk profile and TRV250 Phase...
Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting
December 12, 2019 07:00 ET | Trevena Inc.
Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a...
Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study
November 04, 2019 07:00 ET | Trevena Inc.
Company expects to resubmit NDA for oliceridine in Q1 2020  Acute migraine proof-of-concept study for TRV250 initiated  Company to host conference call at 8:30 a.m. EST CHESTERBROOK, Pa., Nov. 04,...